Global Recombinant Human Epidermal Growth Factor Topical Solution Market Growth 2025-2031

Publication ID:

LPI08251324

Publication Date:

August 4, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Human Epidermal Growth Factor Topical Solution market size is predicted to grow from US$ 366 million in 2025 to US$ 617 million in 2031; it is expected to grow at a CAGR of 9.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant human epidermal growth factor topical solution is a highly active biological agent used to promote skin repair and tissue regeneration. It is widely used in wound care, cosmetic dermatology, burn plastic surgery and other fields. Through genetic recombination technology, this product efficiently expresses proteins with the same structure as the human body's natural epidermal growth factor (EGF) in carriers such as Escherichia coli or yeast, and has good biocompatibility and high biological activity. After topical application, EGF can bind to the skin surface receptors, stimulate the proliferation and migration of keratinocytes and fibroblasts, promote collagen production, accelerate wound healing, and improve the quality of tissue repair. The solution is usually a colorless and transparent liquid and can be used for laser surgery, acne scars, chronic ulcers, skin cracks, and injuries caused by radiotherapy and chemotherapy.
United States market for Recombinant Human Epidermal Growth Factor Topical Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human Epidermal Growth Factor Topical Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human Epidermal Growth Factor Topical Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human Epidermal Growth Factor Topical Solution players cover Promega, STEMCELL Technologies, Abbkine, Shanghai Haohai Biological Technology, QED Bioscience, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淩ecombinant Human Epidermal Growth Factor Topical Solution Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Epidermal Growth Factor Topical Solution sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Epidermal Growth Factor Topical Solution sales for 2025 through 2031. With Recombinant Human Epidermal Growth Factor Topical Solution sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Epidermal Growth Factor Topical Solution industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Epidermal Growth Factor Topical Solution landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Epidermal Growth Factor Topical Solution portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Epidermal Growth Factor Topical Solution market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Epidermal Growth Factor Topical Solution and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Epidermal Growth Factor Topical Solution.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Epidermal Growth Factor Topical Solution market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
20,000 IU/Bottle
50,000 IU/Bottle
75,000 IU/Bottle
100,000 IU/Bottle
Segmentation by Application:
Burn Wound
Chronic Ulcer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Promega
STEMCELL Technologies
Abbkine
Shanghai Haohai Biological Technology
QED Bioscience
Proteintech
Corning
BioLegend
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Epidermal Growth Factor Topical Solution market?
What factors are driving Recombinant Human Epidermal Growth Factor Topical Solution market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Epidermal Growth Factor Topical Solution market opportunities vary by end market size?
How does Recombinant Human Epidermal Growth Factor Topical Solution break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Human Epidermal Growth Factor Topical Solution by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Human Epidermal Growth Factor Topical Solution by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Human Epidermal Growth Factor Topical Solution Segment by Type
2.2.1 20,000 IU/Bottle
2.2.2 50,000 IU/Bottle
2.2.3 75,000 IU/Bottle
2.2.4 100,000 IU/Bottle
2.3 Recombinant Human Epidermal Growth Factor Topical Solution Sales by Type
2.3.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Human Epidermal Growth Factor Topical Solution Sale Price by Type (2020-2025)
2.4 Recombinant Human Epidermal Growth Factor Topical Solution Segment by Application
2.4.1 Burn Wound
2.4.2 Chronic Ulcer
2.4.3 Others
2.5 Recombinant Human Epidermal Growth Factor Topical Solution Sales by Application
2.5.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Human Epidermal Growth Factor Topical Solution Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Breakdown Data by Company
3.1.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Revenue by Company (2020-2025)
3.2.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Human Epidermal Growth Factor Topical Solution Sale Price by Company
3.4 Key Manufacturers Recombinant Human Epidermal Growth Factor Topical Solution Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Epidermal Growth Factor Topical Solution Product Location Distribution
3.4.2 Players Recombinant Human Epidermal Growth Factor Topical Solution Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Recombinant Human Epidermal Growth Factor Topical Solution by Geographic Region
4.1 World Historic Recombinant Human Epidermal Growth Factor Topical Solution Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Human Epidermal Growth Factor Topical Solution Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Human Epidermal Growth Factor Topical Solution Sales Growth
4.4 APAC Recombinant Human Epidermal Growth Factor Topical Solution Sales Growth
4.5 Europe Recombinant Human Epidermal Growth Factor Topical Solution Sales Growth
4.6 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution Sales Growth
5 Americas
5.1 Americas Recombinant Human Epidermal Growth Factor Topical Solution Sales by Country
5.1.1 Americas Recombinant Human Epidermal Growth Factor Topical Solution Sales by Country (2020-2025)
5.1.2 Americas Recombinant Human Epidermal Growth Factor Topical Solution Revenue by Country (2020-2025)
5.2 Americas Recombinant Human Epidermal Growth Factor Topical Solution Sales by Type (2020-2025)
5.3 Americas Recombinant Human Epidermal Growth Factor Topical Solution Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Epidermal Growth Factor Topical Solution Sales by Region
6.1.1 APAC Recombinant Human Epidermal Growth Factor Topical Solution Sales by Region (2020-2025)
6.1.2 APAC Recombinant Human Epidermal Growth Factor Topical Solution Revenue by Region (2020-2025)
6.2 APAC Recombinant Human Epidermal Growth Factor Topical Solution Sales by Type (2020-2025)
6.3 APAC Recombinant Human Epidermal Growth Factor Topical Solution Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Human Epidermal Growth Factor Topical Solution by Country
7.1.1 Europe Recombinant Human Epidermal Growth Factor Topical Solution Sales by Country (2020-2025)
7.1.2 Europe Recombinant Human Epidermal Growth Factor Topical Solution Revenue by Country (2020-2025)
7.2 Europe Recombinant Human Epidermal Growth Factor Topical Solution Sales by Type (2020-2025)
7.3 Europe Recombinant Human Epidermal Growth Factor Topical Solution Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution by Country
8.1.1 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Human Epidermal Growth Factor Topical Solution Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Epidermal Growth Factor Topical Solution
10.3 Manufacturing Process Analysis of Recombinant Human Epidermal Growth Factor Topical Solution
10.4 Industry Chain Structure of Recombinant Human Epidermal Growth Factor Topical Solution
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Epidermal Growth Factor Topical Solution Distributors
11.3 Recombinant Human Epidermal Growth Factor Topical Solution Customer
12 World Forecast Review for Recombinant Human Epidermal Growth Factor Topical Solution by Geographic Region
12.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Market Size Forecast by Region
12.1.1 Global Recombinant Human Epidermal Growth Factor Topical Solution Forecast by Region (2026-2031)
12.1.2 Global Recombinant Human Epidermal Growth Factor Topical Solution Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Human Epidermal Growth Factor Topical Solution Forecast by Type (2026-2031)
12.7 Global Recombinant Human Epidermal Growth Factor Topical Solution Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Promega
13.1.1 Promega Company Information
13.1.2 Promega Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.1.3 Promega Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Promega Main Business Overview
13.1.5 Promega Latest Developments
13.2 STEMCELL Technologies
13.2.1 STEMCELL Technologies Company Information
13.2.2 STEMCELL Technologies Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.2.3 STEMCELL Technologies Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 STEMCELL Technologies Main Business Overview
13.2.5 STEMCELL Technologies Latest Developments
13.3 Abbkine
13.3.1 Abbkine Company Information
13.3.2 Abbkine Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.3.3 Abbkine Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Abbkine Main Business Overview
13.3.5 Abbkine Latest Developments
13.4 Shanghai Haohai Biological Technology
13.4.1 Shanghai Haohai Biological Technology Company Information
13.4.2 Shanghai Haohai Biological Technology Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.4.3 Shanghai Haohai Biological Technology Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Shanghai Haohai Biological Technology Main Business Overview
13.4.5 Shanghai Haohai Biological Technology Latest Developments
13.5 QED Bioscience
13.5.1 QED Bioscience Company Information
13.5.2 QED Bioscience Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.5.3 QED Bioscience Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 QED Bioscience Main Business Overview
13.5.5 QED Bioscience Latest Developments
13.6 Proteintech
13.6.1 Proteintech Company Information
13.6.2 Proteintech Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.6.3 Proteintech Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Proteintech Main Business Overview
13.6.5 Proteintech Latest Developments
13.7 Corning
13.7.1 Corning Company Information
13.7.2 Corning Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.7.3 Corning Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Corning Main Business Overview
13.7.5 Corning Latest Developments
13.8 BioLegend
13.8.1 BioLegend Company Information
13.8.2 BioLegend Recombinant Human Epidermal Growth Factor Topical Solution Product Portfolios and Specifications
13.8.3 BioLegend Recombinant Human Epidermal Growth Factor Topical Solution Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 BioLegend Main Business Overview
13.8.5 BioLegend Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂